Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Krebs

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Journal of Neuro-Oncology|May 29, 2023
Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CTLily A McLaughlin, Onur Yildirim, Marc K Rosenblum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Neuro-Oncology|August 23, 2022
Correction to: Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastasesBrandon S Imber, Robert J Young, Kathryn Beal, et al.
Journal of Neuro-Oncology|July 27, 2022
Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastasesBrandon S Imber, Robert J Young, Kathryn Beal, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2025
Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In VivoHamid Reza Mirzaei, Samantha Lovibond, Leah Gajecki, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 6, 2025
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [<sup>177</sup>Lu]Lu-PSMA-617Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid MalignanciesLeah Gajecki, Irina V Lebedeva, Yu-Rou Liao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2013
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastomaMeenakshi Hegde, Amanda Corder, Kevin K H Chow, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
The Journal of Clinical Investigation|July 1, 2021
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escapeMeenakshi Hegde, Malini Mukherjee, Zakaria Grada, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of Neuro-Oncology|May 29, 2023
Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CTLily A McLaughlin, Onur Yildirim, Marc K Rosenblum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Neuro-Oncology|August 23, 2022
Correction to: Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastasesBrandon S Imber, Robert J Young, Kathryn Beal, et al.
Journal of Neuro-Oncology|July 27, 2022
Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastasesBrandon S Imber, Robert J Young, Kathryn Beal, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2025
Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In VivoHamid Reza Mirzaei, Samantha Lovibond, Leah Gajecki, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 6, 2025
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [<sup>177</sup>Lu]Lu-PSMA-617Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid MalignanciesLeah Gajecki, Irina V Lebedeva, Yu-Rou Liao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2013
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastomaMeenakshi Hegde, Amanda Corder, Kevin K H Chow, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
The Journal of Clinical Investigation|July 1, 2021
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escapeMeenakshi Hegde, Malini Mukherjee, Zakaria Grada, et al.
Pageof 6